2.2 Cardiovascular & Vasoactive Pharmacotherapy

Cardiovascular & Vasoactive Pharmacotherapy

Advanced Principles of Hemodynamic Support

The management of profound hemodynamic instability and shock is a defining responsibility of the AGACNP in the intensive care unit. Shock is fundamentally a state of cellular dysoxia due to a mismatch between oxygen delivery and oxygen consumption. Vasoactive pharmacotherapy, comprising vasopressors to increase vascular tone and inotropes to augment cardiac contractility, forms the cornerstone of restoring adequate tissue perfusion. Mastery of this domain requires an intricate understanding of adrenergic receptor pharmacology and the specific pathophysiological mechanisms driving each classification of shock.

Receptor Pharmacology and Localization

The sympathetic nervous system and exogenous catecholamines exert their cardiovascular effects by binding to specific membrane-bound G-protein coupled receptors.

• Alpha-1 (α1) Receptors: Located predominantly in the smooth muscle of the peripheral, splanchnic, and renal vasculature. Stimulation activates phospholipase C, leading to intense vasoconstriction. This dramatically increases systemic vascular resistance (SVR) and venous return, ultimately raising blood pressure.
• Beta-1 (β1) Receptors: Located primarily in the myocardium and the sinoatrial/atrioventricular nodes. Stimulation activates adenylyl cyclase, increasing intracellular cyclic AMP (cAMP) and calcium. This enhances the rate of myocardial contraction (chronotropy), the force of myocardial contraction (inotropy), and the velocity of electrical conduction (dromotropy), thereby significantly augmenting cardiac output.
• Beta-2 (β2) Receptors: Located in vascular smooth muscle (especially skeletal muscle beds) and bronchial smooth muscle. Stimulation increases cAMP, leading to smooth muscle relaxation, causing vasodilation (decreasing SVR) and profound bronchodilation.
• Dopaminergic (DA) Receptors: Distributed in renal, splanchnic, coronary, and cerebral vascular beds. Low-level stimulation classically mediates localized vasodilation, though the clinical utility of 'renal-dose dopamine' has been thoroughly debunked.
• Vasopressin (V1) Receptors: Non-adrenergic receptors located strictly in vascular smooth muscle. Stimulation causes potent vasoconstriction independent of catecholamine pathways.

Vasopressors: Agents of Vasoconstriction

Vasopressors are primarily utilized to elevate mean arterial pressure (MAP) in states of distributive shock, characterized by profound pathological vasodilation (low SVR).

Norepinephrine (Levophed): Norepinephrine is a potent α1 receptor agonist with clinically significant but modest β1 activity. It profoundly increases SVR and MAP through intense vasoconstriction. Its mild β1 inotropic effect helps preserve or slightly augment cardiac output, counteracting the potential decrease in stroke volume that might otherwise occur against a sharply increased afterload. Due to its balanced and powerful hemodynamic profile, norepinephrine is unequivocally the first-line vasopressor in septic, cardiogenic, and undifferentiated shock.

Epinephrine: Epinephrine is a highly potent, non-selective agonist of α1, β1, and β2 receptors, and its clinical effects are famously dose-dependent. At lower infusion rates (e.g., 0.01 - 0.05 mcg/kg/min), β1 and β2 effects predominate, resulting in increased cardiac contractility, tachycardia, and a net decrease in SVR due to β2-mediated vasodilation. At higher infusion rates, powerful α1-mediated vasoconstriction dominates the clinical picture. It is the absolute drug of choice for anaphylactic shock and is frequently deployed as a second-line agent in refractory septic shock or for potent inotropic support in severe cardiogenic shock. A ubiquitous and confounding side effect is transient hyperlactatemia, driven by β2-mediated stimulation of skeletal muscle glycogenolysis and glycolysis, which must be differentiated from lactate production due to persistent tissue ischemia.

Vasopressin (Antidiuretic Hormone): Vasopressin is a synthetic peptide hormone that binds directly to V1 receptors in vascular smooth muscle, causing profound vasoconstriction independent of the adrenergic system. In states of severe shock, endogenous vasopressin stores are rapidly depleted. Administering exogenous vasopressin effectively reverses this relative deficiency. It is most commonly utilized as a second-line 'catecholamine-sparing' agent in septic shock to reduce the required dosage of norepinephrine and minimize adrenergic toxicity (e.g., tachyarrhythmias, profound peripheral ischemia). It is typically administered at a fixed, non-titrated rate (e.g., 0.03 to 0.04 units/min).

Phenylephrine (Neo-Synephrine): Phenylephrine is a pure, unadulterated α1 agonist, inducing pure vasoconstriction with zero β activity. Because it entirely lacks β1 inotropic or chronotropic effects, the sudden and steep increase in SVR (afterload) frequently triggers a baroreceptor-mediated reflex bradycardia, which can consequently cause a dangerous decrease in stroke volume and overall cardiac output. It is primarily indicated as salvage therapy in vasodilatory shock where extreme tachycardia precludes the use of norepinephrine, in neurogenic shock to counteract loss of sympathetic tone, or for very brief periods during anesthesia-induced hypotension.

Dopamine: Dopamine is an endogenous catecholamine precursor whose clinical effects are highly complex and dose-dependent. At low doses (1-3 mcg/kg/min), DA receptors are stimulated. At medium doses (3-10 mcg/kg/min), β1 receptors are stimulated, increasing contractility and heart rate. At high doses (10-20 mcg/kg/min), α1 receptors are finally recruited, causing vasoconstriction. Due to its significant arrhythmogenic potential, higher mortality rates in cardiogenic shock compared to norepinephrine, and unpredictable dose-response curve, dopamine has largely fallen out of favor and is relegated to second-line therapy for symptomatic bradycardia.

Inotropes: Augmenting Contractility

Inotropes are exclusively utilized to augment myocardial contractility in the setting of severe left or right ventricular dysfunction and classic cardiogenic shock.

Dobutamine: Dobutamine is a synthetic catecholamine engineered for strong β1 and mild β2 receptor activity, with negligible α1 effects. Its primary clinical outcome is significant positive inotropy with modest chronotropy, markedly increasing cardiac output. Importantly, the mild β2 activity frequently causes systemic vasodilation, which can lead to clinically significant hypotension, especially if the patient is relatively hypovolemic. It is a preferred first-line inotrope for severe decompensated heart failure or cardiogenic shock, provided the patient is not already profoundly hypotensive.

Milrinone: Milrinone belongs to a distinct class of medications known as phosphodiesterase-3 (PDE3) inhibitors. By preventing the intracellular breakdown of cyclic AMP (cAMP) in both cardiac myocytes and vascular smooth muscle, it simultaneously produces potent positive inotropy and profound vasodilation, earning it the moniker of an "inodilator." A major advantage is that it acts entirely independent of beta-adrenergic receptors, making it highly effective in patients receiving chronic beta-blocker therapy who might be refractory to dobutamine. However, its significant vasodilatory effects frequently precipitate systemic hypotension, often necessitating concurrent administration of a vasopressor like norepinephrine to maintain MAP. Additionally, it has a long half-life and requires strict dose adjustments in the setting of renal failure to prevent severe accumulation and toxicity.

Clinical Receptor Profile Matrix